Pyridazinedione-based heterobicyclic covalent linkers and methods and applications thereof
US-2024425465-A1 · Dec 26, 2024 · US
US2017002012A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2017002012-A1 |
| Application number | US-201515113730-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jan 26, 2015 |
| Priority date | Jan 24, 2014 |
| Publication date | Jan 5, 2017 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A process is provided, comprising reacting a (hetero)aryl 1,3-dipole compound with a (hetero)cycloalkyne, wherein the (hetero)aryl 1,3-dipole compound comprises a 1,3-dipole functional group bonded to a (hetero)aryl group, and wherein the (hetero)aryl 1,3-dipole compound is a (hetero)aryl azide or a (hetero)aryl diazo compound; wherein: (i) the (hetero)aryl group of the (hetero)aryl 1,3-dipole compound comprises a substituent (ii) the (hetero)aryl group of the (hetero)aryl 1,3-dipole compound is an electron-poor (hetero)aryl group and wherein the (hetero)cycloalkyne is a (hetero)cyclooctyne or a (hetero)cyclononyne according to Formula (1). The invention also relates to the products obtainable by the process according to the invention.
Opening claim text (preview).
1 - 20 . (canceled) 21 . A process comprising reacting a (hetero)aryl 1,3-dipole compound with a (hetero)cycloalkyne, wherein: a (hetero)aryl 1,3-dipole compound is defined as a compound comprising a 1,3-dipole functional group, wherein the 1,3-dipole functional group is bonded to a (hetero)aryl group, and wherein the (hetero)aryl 1,3-dipole compound is a (hetero)aryl azide or a (hetero)aryl diazo compound; wherein: (i) the (hetero)aryl group of the (hetero)aryl 1,3-dipole compound comprises one or more substituents having a positive value for the para-Hammett substituent constant σ p and/or the meta-Hammett substituent constant σ m , and/or (ii) the (hetero)aryl group of the (hetero)aryl 1,3-dipole compound is an electron-poor (hetero)aryl group, wherein an electron-poor (hetero)aryl group is: (ii-a) a (hetero)aryl group wherein the (hetero)aromatic ring system is bearing a positive charge, and/or (ii-b) a (hetero)aryl group wherein the ratio {number of π-electrons present in the (hetero)aromatic ring system}: {number of protons present in the nuclei of the (hetero)aromatic ring system} is lower than 0.167 for a 6-membered ring, or lower than 0.200 for a 5-membered ring; wherein the (hetero)cycloalkyne is an aliphatic (hetero)cycloalkyne, wherein an aliphatic (hetero)cycloalkyne is defined as a (hetero)cycloalkyne wherein both sp 1 C-atoms of the (hetero)cycloalkyne carbon-carbon triple bond are bonded to an sp 3 C-atom; and wherein the (hetero)cycloalkyne is a (hetero)cyclooctyne or a (hetero)cyclononyne according to Formula (1): wherein: when the (hetero)cycloalkyne is a (hetero)cyclooctyne: a is 1, 2, 3 or 4; a′ is 1, 2, 3 or 4; a″ is 1, 2, 3 or 4; with the proviso that a+a′+a″=4; and n is 0-8; or when the (hetero)cycloalkyne is a (hetero)cyclononyne: a is 1, 2, 3, 4 or 5; a′ is 1, 2, 3, 4 or 5; a″ is 1, 2, 3, 4 or 5; with the proviso that a+a′+a″=5; and n is 0-10; R 1 is independently selected from the group consisting of —OR 2 , —NO 2 , —CN, —S(O) 2 R 2 , C 1 -C 24 alkyl groups, C 3 -C 24 cycloalkyl groups, C 2 -C 24 (hetero)aryl groups, C 3 -C 24 alkyl(hetero)aryl groups and C 3 -C 24 (hetero)arylalkyl groups, wherein the alkyl groups, cycloalkyl groups, (hetero)aryl groups, alkyl(hetero)aryl groups and (hetero)arylalkyl groups are optionally substituted, wherein the alkyl groups, cycloalkyl groups, alkyl(hetero)aryl groups and (hetero)arylalkyl groups are optionally interrupted by one or more heteroatoms selected from the group consisting of O, S and N, and wherein R 2 is independently selected from the group consisting of hydrogen, halogen, C 1 -C 24 alkyl groups, C 3 -C 24 cycloalkyl groups, C 2 -C 24 (hetero)aryl groups, C 3 -C 24 alkyl(hetero)aryl groups and C 3 -C 24 (hetero)arylalkyl groups; B and B′ are independently selected from the group consisting of O, S, C(O), NR 3 and C(R 3 ) 2 , wherein R 3 is independently selected from the group consisting of hydrogen, R 1 or (L) p -(A) r ; optionally, when n is 2 or more, two R 1 groups may together form a (hetero)cycloalkyl group, the (hetero)cycloalkyl group optionally being substituted with an (L) p -(A) r substituent; optionally, when a″ is 2 or more and n is 2 or more, two R 1 groups present on adjacent a″-C-atoms may together form a (hetero)aryl group, the (hetero)aryl group optionally being substituted with an (L) p -(A) r substituent; p is 0 or 1; r is 1-4; L is a linker; A is independently selected from the group consisting of D, E and Q, wherein D, E and Q are as defined below; q is 0-4; with the proviso that if q is 0, then B and/or B′ is NR 3 wherein R 3 is (L) p -(A) r , and/or B and/or B′ is C(R 3 ) 2 wherein one or more R 3 is (L) p -(A) r , and/or n is 2 or more and two R 1 groups together form a (hetero)cycloalkyl group wherein the (hetero)cycloalkyl group is substituted with an (L) p -(A) r substituent, and/or a″ is 2 or more and n is 2 or more and two R 1 groups present on adjacent a″-C-atoms together form a (hetero)aryl group wherein the (hetero)aryl group is substituted with an (L) p -(A) r substituent; D is a molecule of interest; E is a solid surface; and Q is a functional group. 22 . The process according to claim 21 , wherein the molecule of interest is selected from the group consisting of a reporter molecule, a diagnostic compound, an active substance, an enzyme, an amino acid, a (non-catalytic) protein, a peptide, a polypeptide, an oligonucleotide, a monosaccharide, an oligosaccharide, a polysaccharide, a glycan, a (poly)ethylene glycol diamine, a polyethylene glycol chain, a polyethylene oxide chain, a polypropylene glycol chain, a polypropylene oxide chain and a 1,x-diaminoalkane, wherein x is the number of carbon atoms in the alkane. 23 . The process according to claim 21 , wherein the solid surface is selected from the group consisting of a functional surface, a nanomaterial, a carbon nanotube, a fullerene, a virus capsid, a metal surface, a metal alloy surface and a polymer surface. 24 . The process according to claim 21 , wherein Q is selected from the groups consisting of hydrogen, halogen, R 11 , —CH═C(R 11 ) 2 , —C≡CR 11 , —[C(R 11 ) 2 C(R 11 ) 2 O] q —R 11 wherein q is in the range of 1 to 200, —CN, —N 3 , — NCX, —XCN, —XR 11 , —N(R 11 ) 2 , — + N(R 11 ) 3 , —C(X)N(R 11 ) 2 , —C(R 11 ) 2 XR 11 , —C(X)R 11 , —C(X)XR 11 , —S(O)R 11 , —S(O) 2 R 11 , —S(O)OR 11 , —S(O) 2 OR 11 , —S(O)N(R 11 ) 2 , —S(O) 2 N(R 11 ) 2 , —OS(O)R 11 , —OS(O) 2 R 11 , —OS(O)OR 11 , —OS(O) 2 OR 11 , —P(O)(R 11 )(OR 11 ), —P(O)(OR 11 ) 2 , —OP(O)(OR 11 ) 2 , —Si(R 11 ) 3 , —XC(X) R 11 , —XC(X)XR 11 , —XC(X)N(R 11 ) 2 , —N(R 11 )C(X)R 11 , —N(R 11 )C(X)XR 11 and —N(R 11 )C(X)N(R 11 ) 2 , wherein X is oxygen or sulphur and wherein R 11 is independently selected from the group consisting of hydrogen, halogen, C 1 -C 24 alkyl groups, C 3 -C 24 cycloalkyl groups, C 2 -C 24 (hetero)aryl groups, C 3 -C 24 alkyl(hetero)aryl groups and C 3 -C 24 (hetero)arylalkyl groups, the C 1 -C 24 alkyl groups, C 3 -C 24 cycloalkyl groups, C 2 -C 24 (hetero)aryl groups, C 3 -C 24 alkyl(hetero)aryl groups and C 3 -C 24 (hetero)arylalkyl groups optionally substituted and optionally interrupted by one or more heteroatoms selected from O and N. 25 . The process according to claim 21 , wherein the (hetero)aryl 1,3-dipole compound is according to Formula (2): wherein: t is 0 or 1; u is 1-4; g is 0 or 1; m is 0-8; with the proviso that when m is 0, then T is an electron-poor (hetero)aryl group, wherein an electron-poor (hetero)aryl group is as defined in claim 21 ; Z is an azide functional group or a diazo functional group; L′ is a linker; A′ is independently selected from the group consisting of D, E and Q, wherein D, E and Q are as defined in claim 21 ; T is selected from the group consisting of (hetero)aryl groups; R 4 is independently selected from the group consisting of electron-withdrawing substituents having a positive value for the para-Hammett substituent constant σ p and/or the meta-Hammett substituent constant σ m ; and W is selected from the group consisting of C 1 -C 24 alkylene groups, C 2 -C 24 alkenylene groups, C 3 -C 24 cycloalkylene groups, C 2 -C 24 (hetero)arylene groups, C 3 -C 24 alkyl(hetero)arylene groups and C 3 -C 24 (hetero)arylalkylene groups, wherein the alkylene groups, alkenylene groups, cycl
Ortho-condensed systems · CPC title
Human Necessities · mapped topic
Human Necessities · mapped topic
with the saccharide radical esterified by phosphoric or polyphosphoric acids · CPC title
alpha-Glycoproteins · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.